Bifogade filer
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE A RELEASE, PUBLICATION OR DISTRIBUTION WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
On 19 December 2024, the respective board of directors of Surgical Science Sweden AB (“Surgical Science” or the “Company”) and Intelligent Ultrasound Group PLC (“Intelligent Ultrasound”) announced that they have reached agreement on the terms of a recommended cash acquisition to be made by Surgical Science for the entire issued and to be issued ordinary share capital of Intelligent Ultrasound (the “Intelligent Ultrasound Acquisition”).
Surgical Science is pleased to announce that the Company has today made an announcement in the United Kingdom via the Regulatory News Service relating to the publication of the Scheme Document in respect of the Intelligent Ultrasound Acquisition (the “RNS Announcement”). A copy of the RNS Announcement is attached to this press release and will also be made available on Surgical Science’s website (including the full text of the Scheme Document, as referred to in the RNS Announcement), subject to certain restrictions relating to persons resident in certain restricted jurisdictions.
Surgical Science has appointed Pareto Securities AB as Financial Advisor and Strand Hanson Limited as UK Financial Advisor for the Intelligent Ultrasound Acquisition. Baker McKenzie LLP is acting as legal adviser to Surgical Science, and PwC acts as due diligence adviser to Surgical Science in connection with the Intelligent Ultrasound Acquisition.
Gothenburg, Sweden, January 15, 2025
Surgical Science Sweden AB (publ)
The Board of Directors
The RNS Announcement, in its entirety, is available through the attachment or via:
https://surgicalscience/investor-relations/#press-releases